Equibles does not estimate personal net worth.
Get an email with a short summary when Ani Pharmaceuticals Inc publishes a filing, an earnings call transcript or a press release.
Get ANIP alertsStephen Carey is recorded as CFO at Ani Pharmaceuticals Inc (ANIP). The newest filing on record that lists Stephen Carey as CFO at Ani Pharmaceuticals Inc (ANIP) is dated April 9, 2026. The proxy statement of Ani Pharmaceuticals Inc reports total compensation of $3,251,862 for Stephen Carey in fiscal 2025, including a base salary of $521,031. Disclosed compensation is on record for 9 fiscal years. Stephen Carey has spoken on 21 earnings calls and 2 other investor events across 1 company, most recently for Ani Pharmaceuticals Inc on September 14, 2026. Ani Pharmaceuticals Inc is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at Ani Pharmaceuticals Inc includes Nikhil Lalwani (CEO and Board Member), Patrick D. Walsh (CEO and Board Member), Thomas J. Haughey (Chairman) and 7 others.
“First of all, I should start off by just saying the culmination of all of the efforts and the business building that Nikhil has been discussing, we're very pleased with the way that's manifesting on our balance sheet.”
“Obviously, the balance sheet has developed. I think when Nikhil first started at the company, we had roughly $7 million of cash left. And as you cite, Raul, as of June of this year, we've grown that to $360 million as we've built the company out.”
“Now I'll review our second quarter results in 2026 guidance in more detail. Starting with slide 17, A&I total net revenues were $266 million in the second quarter, up 26% over the prior year period.”
“I'll now review our first quarter results and 2026 guidance in more detail. Starting with slide 13, A&I total net revenues were $237.5 million in the first quarter, up 20% over the prior year period.”
“I'll review our fourth quarter and full year 2025 results and 2026 guidance in more detail. In 2025, we delivered on our financial commitments, generating robust top and bottom line growth and significant cash flows.”
Start not stated–present
Last confirmed April 9, 2026
Drug Manufacturers - Specialty & Generic · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Ani Pharmaceuticals Inc (ANIP) | Senior Vice President, Finance and Chief Financial Officer | $521,031 | $3,251,862 |
| 2024 | Ani Pharmaceuticals Inc (ANIP) | Senior Vice President and Chief Financial Officer | $509,857 | $2,850,468 |
| 2023 | Ani Pharmaceuticals Inc (ANIP) | Senior Vice President and Chief Financial Officer | $509,857 | $2,576,088 |
| 2022 | Ani Pharmaceuticals Inc (ANIP) | Senior Vice President and Chief Financial Officer | $505,859 | $2,039,584 |
| 2021 | Ani Pharmaceuticals Inc (ANIP) | Senior Vice President and Chief Financial Officer | $491,319 | $2,850,554 |
| 2020 | Ani Pharmaceuticals Inc (ANIP) | Senior Vice President and Chief Financial Officer | $474,271 | $2,754,577 |
| 2019 | Ani Pharmaceuticals Inc (ANIP) | Senior Vice President, Finance and Chief Financial Officer | $456,877 | $2,156,392 |
| 2018 | Ani Pharmaceuticals Inc (ANIP) | Senior Vice President, Finance and Chief Financial Officer | $431,157 | $1,438,750 |
| 2017 | Ani Pharmaceuticals Inc (ANIP) | Vice President, Finance and Chief Financial Officer | $389,233 | $1,246,557 |
